Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Lutathera (lutetium Lu 177 dotatate) is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.
• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Median Progression-Free Survival (PFS) in patients re-treated with ^177Lu-PRRT was 12.52 months (95% CI 9.82-15.22), with a median Overall Survival (OS) of 26.78 months (95% CI 18.73-34.83), and a Disease Control Rate (DCR) of 71% (95% CI 66-75).
• In patients with differentiated thyroid cancer (RR-DTC), the biochemical response was 25.3%, and the objective response was 10.5%. For metastatic medullary thyroid carcinoma (MTC), the biochemical response was 37.2%, and the objective response was 10.6%.
• The Disease Response Rate (DRR) in neuroendocrine tumors (NETs) was 27.58% (95% CI 21.03-35.27%) by RECIST criteria and 20.59% (95% CI 10.89-35.51%) by SWOG criteria, with Disease Control Rates (DCR) of 79.14% (95% CI 75.83-82.1%) and 78.28% (95% CI 74.39-81.72%) respectively.
• Grade 3/4 adverse events occurred in 5% of patients (95% CI 2-8), with few grade 3/4 renal toxicities (0% [95% CI 0-1]), and no cases of Myelodysplastic Syndrome or Acute Myeloid Leukemia (0% [95% CI 0-2]).
• Minimal adverse effects reported, including fatigue, nausea, vomiting, and hormonal disorders.
• There is no population types or subgroups information available in the reviewed studies.